StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Worldwide Revenue ($M) ($M)

Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A

QuarterlyAnnual
Latest, Q3 2026
2,185
Period ended Sep 30, 2026
Change on a year earlier
+6.2%
2,057 in Q3 2025
History
44 quarters
Since Q4 2015
Sources
44
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDiabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Worldwide Revenue ($M) ($M)Year on yearSource
Q3 2026Sep 30, 20262,185+6.2%SEC Filing (0001628280-26-066601) ↗
Q2 2026Jun 30, 20262,188+10.4%SEC Filing (0001628280-26-048377) ↗
Q1 2026Mar 31, 20262,080+13.8%SEC Filing (0001628280-26-025365) ↗
Q4 2025Dec 31, 20252,133+14.5%SEC Filing (0001628280-26-002982) ↗
Q3 2025Sep 30, 20252,057+19.2%SEC Filing (0001628280-25-045049) ↗
Q2 2025Jun 30, 20251,981+20.2%SEC Filing (0001628280-25-035135) ↗
Q1 2025Mar 31, 20251,827+16.4%SEC Filing (0001628280-25-017924) ↗
Q4 2024Dec 31, 20241,863+20.0%SEC Filing (0001628280-25-002092) ↗
Q3 2024Sep 30, 20241,725+17.2%SEC Filing (0001628280-24-042893) ↗
Q2 2024Jun 30, 20241,648+15.7%SEC Filing (0001628280-24-032182) ↗
Q1 2024Mar 31, 20241,569+19.5%SEC Filing (0001628280-24-016497) ↗
Q4 2023Dec 31, 20231,552+22.1%SEC Filing (0001628280-24-002009) ↗
Q3 2023Sep 30, 20231,472+26.1%SEC Filing (0001628280-23-034544) ↗
Q2 2023Jun 30, 20231,424+19.5%SEC Filing (0001628280-23-025156) ↗
Q1 2023Mar 31, 20231,313+16.6%SEC Filing (0001628280-23-012020) ↗
Q4 2022Dec 31, 20221,271+8.5%SEC Filing (0001628280-23-001516) ↗

Breakdown

What makes up diabetes care division (freestyle libre cgm & blood glucose monitoring) — worldwide revenue ($m)

Cite this data

StockData. (2026). Abbott Laboratories Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Worldwide Revenue ($M) ($M), quarterly Q4 2015–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-dc-rev-ww

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.